ArticleEuropean radiology2026
Extranodal extension on MRI after neoadjuvant chemoradiotherapy improves the prognostic contribution of nodal evaluation in rectal cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CT-derived extracellular volume fraction and AI-assisted body composition for predicting neoadjuvant therapy response and prognosis in colorectal cancer.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesEvaluation of extranodal extension (ENE) after neoadjuvant chemoradiotherapy (nCRT) might improve the currently suboptimal prognostic implication of preoperative nodal evaluation in rectal cancer, but evidence is lacking. The aim of this study was to evaluate diagnostic accuracy and prognostic value of MRI-determined ENE after nCRT in rectal cancer. MATERIALS AND
methodsThis single-center study included a prospective developing dataset and a retrospective validation cohort, which enrolled patients who underwent nCRT and surgery from 2021 to 2023 and 2018 to 2019, respectively. In the developing dataset, participants were chronologically divided into training and test sets in 3:1 ratio and multiparametric features were analyzed on MRI before and after nCRT (hereafter, post-nCRT) in nodes that achieved per-node matching with pathology. The diagnostic process was established with logistic analyses and evaluated with areas under the receiver operating characteristic curve (AUCs). In the validation cohort, potential risk factors were evaluated, and Cox analysis was used to explore their association with disease-free survival (DFS).
results208 participants were included in the developing dataset. The post-nCRT process, which incorporated the tail sign and vessel interruption on post-nCRT MRI, yielded AUCs of 0.86 (95% CI: 0.82, 0.89) and 0.83 (95% CI: 0.76, 0.89) in the training and test sets, respectively. In the validation cohort of 123 patients, the presence of ENE on post-nCRT MRI was demonstrated to be an independent risk factor for DFS (p = 0.02).
conclusionThe evaluation of ENE after nCRT better predicts prognosis, whose presence may serve as an indicator of intensified therapy in rectal cancer patients. KEY POINTS: Question Evidence of evaluating the extranodal extension (ENE), a pathological prognostic indicator, on MRI after neoadjuvant chemoradiotherapy (nCRT) is lacking in rectal cancer. Findings ENE could be detected by only two features on post-nCRT MRI, and its presence was associated with poorer disease-free survival. Clinical relevance The preoperative evaluation of ENE after nCRT improved the currently suboptimal contribution of nodal evaluation to prognostication in rectal cancer patients.
Indexed as
Identifiers
40603772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.